TSPAN6 Antibody

What is TSPAN6 and why is it a significant research target?

TSPAN6 (Tetraspanin 6) is a membrane protein encoded by the TSPAN6 gene that belongs to the tetraspanin (TM4SF) protein family. In humans, the canonical TSPAN6 protein consists of 245 amino acid residues with a molecular mass of approximately 27.6 kDa . TSPAN6 has gained research significance due to its involvement in several critical cellular processes:

• It functions as a negative regulator of the RIG-I-like receptor (RLR) signaling pathway, which is crucial for antiviral immune responses

• It undergoes post-translational modifications, particularly glycosylation and Lys-63-linked ubiquitination

• It has been implicated in NF-kappaB signaling pathways, suggesting a role in inflammatory responses

• Recent research has identified its upregulation in gliomas, correlating with unfavorable clinical outcomes and altered immune cell infiltration, positioning it as a potential diagnostic and therapeutic target

The protein is also known by several alternative names, including TM4SF6, A15 homolog, putative NF-kappa-B-activating protein 321, tetraspan TM4SF, tetraspanin TM4-D, and T245 .

What are the primary applications for TSPAN6 antibodies in laboratory research?

TSPAN6 antibodies serve multiple experimental purposes in research settings:

• Western Blot (WB): The most common application for TSPAN6 antibodies, enabling detection of the protein's expression levels and post-translational modifications

• Enzyme-Linked Immunosorbent Assay (ELISA): Used for quantitative measurement of TSPAN6 in biological samples

• Immunohistochemistry (IHC): Applied to visualize TSPAN6 expression patterns in tissue sections, particularly valuable in cancer research

• Co-immunoprecipitation assays: Essential for studying protein-protein interactions, such as TSPAN6's interaction with MAVS and other components of the RLR pathway

• Investigating ubiquitination status: Specifically detecting Lys-63-linked ubiquitination of TSPAN6, which is critical for its regulatory functions

When selecting antibodies for these applications, researchers should consider specificity, species reactivity, and whether the epitope is accessible in the experimental context.

How should researchers validate TSPAN6 antibody specificity in experimental systems?

Proper validation of TSPAN6 antibodies is critical for experimental reliability:

• Positive and negative control samples:

  • Use cell lines with known TSPAN6 expression levels as positive controls

  • Include TSPAN6 knockout or knockdown samples as negative controls

• Multiple detection methods:

  • Compare results across Western blot, immunohistochemistry, and immunofluorescence

  • Verify protein size matches the expected 27.6 kDa for human TSPAN6

• Epitope verification:

  • Consider using antibodies targeting different regions of TSPAN6 (N-terminal vs. C-terminal)

  • The first transmembrane domain is particularly important for TSPAN6 function and interactions

• Cross-reactivity assessment:

  • Test antibody against recombinant TSPAN6 protein

  • Examine potential cross-reactivity with other tetraspanin family members

• Knockdown/Knockout verification:

  • Use shRNA constructs targeting TSPAN6 (e.g., 5′-gctactggtaccgtcattatt-3′, 5′-cctaagagttgctgtaaactt-3′, or 5′-gcttccaactgattggaatct-3′) to create knockdown cell lines for antibody validation

What species reactivity should be considered when selecting TSPAN6 antibodies?

TSPAN6 antibodies are available with reactivity to multiple species, reflecting the evolutionary conservation of this protein:

When studying TSPAN6 in animal models, researchers should verify sequence homology and epitope conservation before selecting an antibody. Gene orthologs have been identified across multiple species including mouse, rat, bovine, frog, chimpanzee, and chicken .

How can researchers effectively study TSPAN6's role in the RLR signaling pathway?

To investigate TSPAN6's function in RLR signaling, researchers should consider these methodological approaches:

• Luciferase reporter assays:

  • Transfect cells with IFN-β-luciferase reporter plasmids along with expression vectors for RLR pathway components (RIG-I, MDA5, MAVS)

  • Co-transfect varying amounts of TSPAN6 expression constructs to assess dose-dependent effects

  • Include TBK1 and TRIF expression plasmids as controls, as TSPAN6 does not affect these pathways

• RNA interference and overexpression studies:

  • Knockdown TSPAN6 using specific siRNAs or shRNAs to enhance RLR-mediated responses

  • Overexpress TSPAN6 to observe inhibition of IFN-β promoter activation

  • Use viral RNA (e.g., influenza A virus RNA) or viral mimetics (e.g., poly(I:C)) as stimuli

• Protein-protein interaction studies:

  • Conduct co-immunoprecipitation assays to detect interactions between TSPAN6 and RLR pathway components

  • Focus particularly on MAVS interaction, which is strongest among RLR components

  • Create and test TSPAN6 deletion mutants, especially the first transmembrane domain (TSPAN6Δ1), which is critical for MAVS interaction

• Ubiquitination analysis:

  • Examine Lys-63-linked ubiquitination of TSPAN6 following RLR pathway activation

  • Investigate how this modification affects TSPAN6-MAVS interaction

These approaches enable comprehensive analysis of how TSPAN6 negatively regulates the RLR pathway by interacting with MAVS and inhibiting downstream signaling.

What methodologies are optimal for investigating TSPAN6's role in tumor biology?

Based on recent findings linking TSPAN6 to glioma biology, researchers should consider these experimental approaches:

• Bioinformatic analysis of TSPAN6 expression:

  • Utilize public databases (TCGA, GEO) to analyze TSPAN6 expression across normal and tumor tissues

  • Compare expression levels between different tumor grades and correlate with clinical outcomes

  • Process raw data using appropriate statistical software (e.g., R4.2.1)

• Differential gene expression analysis:

  • Divide samples into high and low TSPAN6 expression groups

  • Identify differentially expressed genes (DEGs) using criteria of adjusted p-value < 0.05 and |logFC| ≥ 1

  • Perform KEGG and GO enrichment analyses on the DEGs to reveal associated pathways

• Protein-protein interaction (PPI) network analysis:

  • Construct PPI networks using the STRING database (interaction score > 0.4)

  • Import data into Cytoscape (version 3.9.1) and rank nodes based on their degrees using the cytoHubba plugin

  • Identify hub genes associated with TSPAN6 to understand its broader functional context

• In vitro functional studies:

  • Generate stable TSPAN6 knockdown cell lines using lentiviral vectors

  • Assess effects on:

    • Cell proliferation

    • Cell cycle regulation

    • Migration and invasion capabilities

    • Macrophage recruitment

• Immune infiltration analysis:

  • Perform single-sample gene set enrichment analysis (ssGSEA) using the GSVA R package

  • Evaluate correlation between TSPAN6 expression and infiltration of 24 immune cell types

  • Focus particularly on macrophage and neutrophil infiltration, which show positive correlation with TSPAN6 expression

How should researchers design experiments to investigate TSPAN6's potential as an immune checkpoint therapy biomarker?

Recent findings suggest TSPAN6 could serve as a predictive biomarker for immune checkpoint blockade (ICB) therapy response. To investigate this potential:

• Correlation analysis with immune checkpoint molecules:

  • Analyze co-expression patterns between TSPAN6 and established immune checkpoint genes

  • Use Spearman's correlation test to evaluate associations between TSPAN6 and different immune cell populations

• Computational prediction of ICB response:

  • Utilize the Tumor Immune Dysfunction and Exclusion (TIDE) computational system to predict ICB therapy response based on TSPAN6 expression

  • Analyze TSPAN6 expression in relation to factors associated with tumor immune evasion

• Validation using existing treatment cohorts:

  • Access and analyze data from treatment cohorts like the IMvigor210 cohort (treated with anti-PDL1 therapy)

  • Compare TSPAN6 expression levels with documented treatment responses

• Experimental validation:

  • Design in vitro co-culture systems with tumor cells and immune cells to assess how TSPAN6 modulation affects immune cell function

  • Develop animal models with varying TSPAN6 expression levels and evaluate response to immune checkpoint inhibitors

• Mechanistic investigation:

  • Examine how TSPAN6 influences the tumor microenvironment, particularly focusing on:

    • Macrophage polarization

    • T-cell exhaustion markers

    • Cytokine/chemokine production profiles

What techniques are available for studying TSPAN6 ubiquitination and its functional consequences?

TSPAN6 undergoes Lys-63-linked ubiquitination, which is critical for its regulatory functions in the RLR pathway. To study this process:

• Ubiquitination detection methods:

  • Perform immunoprecipitation with TSPAN6 antibodies followed by Western blotting with ubiquitin antibodies

  • Use antibodies specific for Lys-63-linked ubiquitin chains to distinguish from other ubiquitination types

  • Co-express TSPAN6 with MAVS to induce ubiquitination

• Mutational analysis:

  • Generate TSPAN6 deletion mutants, particularly focusing on the first transmembrane domain (TSPAN6Δ1)

  • Test these mutants for:

    • Ubiquitination status

    • Interaction with MAVS

    • Effect on RLR signaling pathway

• Structure-function relationship studies:

  • Compare ubiquitination patterns across different TSPAN6 mutants

  • Correlate ubiquitination status with functional outcomes (e.g., inhibition of IFN-β promoter activation)

  • Identify specific lysine residues that undergo ubiquitination

• Temporal dynamics analysis:

  • Monitor ubiquitination status of TSPAN6 at different time points following RLR pathway activation

  • Correlate changes in ubiquitination with alterations in protein-protein interactions and signaling outcomes

• Deubiquitinase identification:

  • Screen for deubiquitinating enzymes that may regulate TSPAN6 function

  • Assess how modulation of these enzymes affects TSPAN6-dependent regulation of immune responses

How can researchers address nonspecific binding when using TSPAN6 antibodies?

Nonspecific binding is a common challenge when working with TSPAN6 antibodies. Consider these methodological approaches:

• Optimization of blocking conditions:

  • Test different blocking agents (BSA, milk, commercial blocking buffers)

  • Extend blocking time (1-2 hours at room temperature or overnight at 4°C)

  • Include detergents like Tween-20 (0.05-0.1%) in washing buffers

• Antibody dilution optimization:

  • Perform titration experiments to determine optimal antibody concentration

  • Starting recommendations: 1:500-1:2000 for Western blot, 1:100-1:500 for IHC

• Sample preparation considerations:

  • For membrane proteins like TSPAN6, avoid harsh detergents that might disrupt epitope structure

  • Consider non-denaturing conditions if the antibody recognizes conformational epitopes

  • For Western blots, ensure complete transfer of this membrane protein to the membrane

• Control experiments:

  • Include TSPAN6 knockdown samples as negative controls

  • Pre-absorb the antibody with recombinant TSPAN6 protein to confirm specificity

  • Test multiple TSPAN6 antibodies targeting different epitopes

What protocols are recommended for detecting endogenous versus overexpressed TSPAN6?

Detection strategies should be tailored based on whether you're studying endogenous or overexpressed TSPAN6:

• Endogenous TSPAN6 detection:

  • Use highly sensitive antibodies (monoclonal preferred for specificity)

  • Optimize protein loading (typically 20-50 μg total protein)

  • Consider enrichment strategies for membrane proteins

  • For cell lines with low expression, longer exposure times may be necessary

• Overexpressed TSPAN6 detection:

  • Use epitope tags (Myc, FLAG) for easier detection of overexpressed protein

  • Reduce protein loading (typically 10-20 μg total protein)

  • Shorter exposure times to prevent oversaturation

  • Include vector-only controls

• Comparison considerations:

  • When comparing endogenous vs. overexpressed TSPAN6, process samples identically

  • Use dual-color Western blot systems to visualize both on the same membrane

  • Consider semi-quantitative analysis using appropriate loading controls

How should researchers interpret discrepancies between TSPAN6 protein and mRNA expression data?

When studying TSPAN6, researchers may encounter discrepancies between protein and mRNA expression levels:

• Potential explanations for discrepancies:

  • Post-transcriptional regulation (miRNAs targeting TSPAN6 mRNA)

  • Post-translational modifications affecting protein stability

  • Protein localization issues (membrane proteins may be difficult to extract completely)

  • Technical limitations in detection methods

• Verification approaches:

  • Compare multiple antibodies and detection methods

  • Perform pulse-chase experiments to assess protein stability

  • Use proteasome inhibitors to determine if protein degradation is a factor

  • Assess subcellular localization using fractionation techniques

• Integrated analysis:

  • Combine protein-level data (Western blot, IHC) with mRNA data (qPCR, RNA-seq)

  • Consider single-cell analysis to account for cellular heterogeneity

  • Examine correlation patterns across multiple samples/tissues

What are emerging techniques for studying TSPAN6 in the context of the tumor microenvironment?

As TSPAN6 emerges as a potential biomarker in cancer, particularly gliomas, these advanced techniques show promise:

• Spatial transcriptomics and proteomics:

  • Apply techniques like Visium or CODEX to map TSPAN6 expression in the spatial context of tumors

  • Correlate TSPAN6 expression with immune cell infiltration patterns and microenvironmental niches

• Single-cell analysis:

  • Perform single-cell RNA sequencing to identify specific cell populations expressing TSPAN6

  • Combine with protein detection methods (e.g., CITE-seq) to correlate with surface marker expression

• 3D organoid models:

  • Develop patient-derived organoids with varying TSPAN6 expression

  • Use these models to study tumor-immune interactions in a more physiologically relevant context

  • Test effects of TSPAN6 modulation on organoid growth and invasion

• In vivo imaging:

  • Develop fluorescently tagged anti-TSPAN6 antibodies for intravital microscopy

  • Monitor TSPAN6 expression dynamics in tumor models in real-time

• Mass cytometry (CyTOF):

  • Incorporate anti-TSPAN6 antibodies into CyTOF panels

  • Simultaneously assess multiple immune and tumor markers to place TSPAN6 in broader cellular contexts

How might TSPAN6 serve as a therapeutic target, and what approaches show promise?

Based on TSPAN6's functions in immune regulation and tumor biology, several therapeutic strategies warrant investigation:

• Antibody-based approaches:

  • Develop function-blocking antibodies targeting the extracellular domains of TSPAN6

  • Explore antibody-drug conjugates to deliver cytotoxic payloads to TSPAN6-expressing cells

• Small molecule inhibitors:

  • Screen for compounds that disrupt TSPAN6-MAVS interaction

  • Target the first transmembrane domain, which is critical for TSPAN6 function

• RNA interference therapeutics:

  • Design siRNA or shRNA delivery systems targeting TSPAN6

  • Test therapeutic efficacy in pre-clinical glioma models

• Combination therapies:

  • Evaluate TSPAN6 targeting in combination with immune checkpoint inhibitors

  • Investigate synergy with standard-of-care treatments for gliomas

• PROTAC (Proteolysis targeting chimera) approach:

  • Develop PROTACs that can selectively degrade TSPAN6 protein

  • Test whether TSPAN6 degradation enhances anti-tumor immune responses